Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2004-02-05
Target enrollment:
Participant gender:
Summary
Current therapies for Recurrent or Extensive-Stage Small Cell Lung Cancer provide very
limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest
that it may prove beneficial in the treatment of Recurrent or Extensive-Stage Small Cell Lung
Cancer.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on patients with Recurrent or Extensive-Stage Small Cell Lung
Cancer.